Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …

The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …

Introduction: Many patients with oncogene-driven non–small-cell lung cancer (NSCLC)
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …

Background Development of acquired resistance limits the utility of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially
established as second-or third-line treatment of advanced non-small-cell lung cancer …

First-generation reversible EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed
our understanding of advanced non-small-cell lung cancer biology and behavior. The …

Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …

Although the transition to molecularly defined patient subgroups in advanced non-small cell
lung cancer (NSCLC) often leads to dramatic and prolonged responses to an inhibitor of an …

Advances in the management of non-small cell lung cancer (NSCLC) over the past 30 years
have led to small increases in 5-year survival rates across Europe, though further …